E-Book Overview
This volume comprehensively reviews oncology in the precision medicine era of personalized care, latest developments in the field, and indications and clinical trials for the treatment of cancer with targeted therapies, immunotherapy, and epigenetic modulators. It thoroughly addresses concerns of various types of cancers including cancers of the head and neck, lung, colon, esophagus, bladder, pancreas, and breast; melanoma; multiple myeloma; hepatocellular carcinoma; renal cell carcinoma; and sarcomas. It is organized and written in a format that is easy to follow for both clinicians and non-clinical scientists interested in personalized medicine. Chapters cover the identification of the clinical problem and summary of recent findings, tumor biology and heterogeneity, genomics, examples of simple and complex cases, biological pathways, future clinical trials, and financial considerations.
Oncology in the Precision Medicine Era: Value-Based Medicine will serve as a useful resource for medical oncologists and healthcare providers tailoring medicine to the needs of the individual patient, from prevention and diagnosis to treatment and follow up.
E-Book Content
Oncology in the Precision Medicine Era Value-Based Medicine Ravi Salgia Editor 123 Oncology in the Precision Medicine Era Ravi Salgia Editor Oncology in the Precision Medicine Era Value-Based Medicine Editor Ravi Salgia Department of Medical Oncology & Therapeutics Research City of Hope National Medical Center Duarte, CA USA ISBN 978-3-030-31470-5 ISBN 978-3-030-31471-2 (eBook) https://doi.org/10.1007/978-3-030-31471-2 © Springer Nature Switzerland AG 2020 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland Preface Just a few years ago, medicine, as we knew it, revolved around “standards of care,” the best practices of treatment or prevention for “the” patient. In other words, it was a “one-size-fits-all” approach for a given indication. Over the past decade, however, there has been a revolution, and a number of therapies, protocols, and diagnostic products that tend to “personalize” medicine signaling a new era have entered the clinic or come on the horizon. Thus, targeted therapies, tailored for patients with specific genetic alterations in actionable targets, such as oncogenes, have replaced conventional therapies. Such therapies have admittedly fared better with a relatively quick response rate but can be fairly ineffective or, even worse, have u